Rewiring ERBB3 and ERK signaling confers resistance to FGFR1 inhibition in gastrointestinal cancer harbored an ERBB3-E928G mutation.

Author: Xiang YANG ¹ ; Hongxiao WANG ¹ ; Enjun XIE ¹ ; Biyao TANG ¹ ; Qingdian MU ¹ ; Zijun SONG ¹ ; Junyi CHEN ¹ ; Fudi WANG ¹ ; Junxia MIN ²
Author Information

1. The First Affiliated Hospital, Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, 310058, China.
2. The First Affiliated Hospital, Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, 310058, China. junxiamin@zju.edu.cn.
Publication Type:Research Support, Non-U.S. Gov't
MeSH: Amino Acid Substitution; Antineoplastic Agents/pharmacology*; Cell Line, Tumor; Drug Resistance, Neoplasm/genetics*; Gastrointestinal Neoplasms/pathology*; Humans; MAP Kinase Signaling System/genetics*; Mutation, Missense; Receptor, ErbB-3/metabolism*; Receptor, Fibroblast Growth Factor, Type 1/metabolism*
From: Protein & Cell 2020;11(12):915-920
CountryChina
Language:English